AMERICAN FORK, Utah — Research from the University of Tennessee confirms that xylitol (the active ingredient in Xlear Nasal Spray), has a potent ability to block viral adhesion of the SARS-CoV-2, inactivating more than 99.9% of the virus that causes COVID-19.

This new research supports results from research at Utah State and the University of Geneva that show the virucidal activity of the Xlear Nasal Spray. The idea of using something that blocks viral adhesion and a virucidal in a nasal spray could be a game-changer in the fight to slow the spread of Sars-Cov-2, the researchers and the company said.

“We are delighted to be working with Dr. Gustavo Ferrer of the Pulmonary Institute of Aventura to expedite further clinical research of this important product,” said Nathan Jones, Xlear Inc. founder and CEO of Xlear. “This latest data show that at clinically relevant concentrations (at the concentration of Xlear Nasal Spray), xylitol blocks adhesion of more than 99.9% of the Sars-Cov-2 virus in vitro, the GSE works as a virucidal that inactivates more than 99.9% of SARS-CoV-2, which represents a compelling feature for use of this product. This potent one-two punch of blocking viral adhesion and virucidal action is consistent with what the in vitro research shows. Knowing that 90% of the viral load resides in the upper airway makes the nasal spray delivery system a no brainer.

Dr. Gustavo Ferrer added: “We have been working with Xlear for a number of months now and are impressed with the antiviral and virucidal data generated at world-class research institutions against SARS-CoV-2. It is particularly exciting to see a product that has been on the market for over two decades show such a potent and clear anti-viral and virucidal effect against this highly infectious virus. The Xlear Nasal Spray has the potential to be an essential near-term airway cleansing product and therapeutic. Given that it is already available 50,000 retailers nationwide, it could be the most readily available product to help slow the spread of the Sars-Cov-2 virus. We are very interested in completing this research on another great feature of the Xlear Nasal Spray that could complement other prevention measures such as PPE and vaccines.”